Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M A Rodriguez

Showing results (251-260 of 333) with videos related to

Pageof 34
Sort By:
Academic Medicine : Journal of the Association of American Medical Colleges|June 4, 1998
Injury-control education in six U.S. medical schoolsR N Butler, K H Todd, A L Kellermann, et al.
Leukemia & Lymphoma|June 5, 1998
Chromosome breaks and sister chromatid exchange as predictors of second cancers in Hodgkin's diseaseS S Strom, Y Gu, A J Sigurdson, et al.
British Journal of Haematology|December 19, 1998
Paclitaxel plus high-dose cyclophosphamide with G-CSF support in patients with relapsed and refractory aggressive non-Hodgkin's lymphomaA Younes, J Romaguera, O Mesina, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 15, 2001
Down-regulation of dendritic spine and glutamic acid decarboxylase 67 expressions in the reelin haploinsufficient heterozygous reeler mouseW S Liu, C Pesold, M A Rodriguez, et al.
Leukemia & Lymphoma|February 26, 1999
Ninety-six-hour paclitaxel infusion with mitoxantrone and ifosfamide/mesna and consolidation with ESHAP for refractory and relapsed non-Hodgkin's lymphomaJ E Romaguera, F B Hagemeister, P McLaughlin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1996
No effect of 96-hour paclitaxel infusion in patients with relapsed non-Hodgkin's lymphoma refractory to a 3-hour infusion scheduleA Younes, J P Ayoub, F B Hagemeister, et al.
Cancer|July 21, 1998
Colorectal carcinoma survival among hereditary nonpolyposis colorectal carcinoma family membersP Watson, K M Lin, M A Rodriguez-Bigas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 11, 1992
Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphomaJ R Redman, F Cabanillas, W S Velasquez, et al.
International Journal of Radiation Oncology, Biology, Physics|November 10, 2000
Impact of involved field radiotherapy after CHOP-based chemotherapy on stage III-IV, intermediate grade and large-cell immunoblastic lymphomasP J Schlembach, R B Wilder, S L Tucker, et al.
Clinical Lymphoma|November 15, 2001
Non-Hodgkin's lymphoma affecting the testis: is it curable with doxorubicin-based therapy?C Visco, L J Medeiros, O M Mesina, et al.
Pageof 34

Showing results (251-260 of 333) with videos related to

Sort By:
Pageof 34
Academic Medicine : Journal of the Association of American Medical Colleges|June 4, 1998
Injury-control education in six U.S. medical schoolsR N Butler, K H Todd, A L Kellermann, et al.
Leukemia & Lymphoma|June 5, 1998
Chromosome breaks and sister chromatid exchange as predictors of second cancers in Hodgkin's diseaseS S Strom, Y Gu, A J Sigurdson, et al.
British Journal of Haematology|December 19, 1998
Paclitaxel plus high-dose cyclophosphamide with G-CSF support in patients with relapsed and refractory aggressive non-Hodgkin's lymphomaA Younes, J Romaguera, O Mesina, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 15, 2001
Down-regulation of dendritic spine and glutamic acid decarboxylase 67 expressions in the reelin haploinsufficient heterozygous reeler mouseW S Liu, C Pesold, M A Rodriguez, et al.
Leukemia & Lymphoma|February 26, 1999
Ninety-six-hour paclitaxel infusion with mitoxantrone and ifosfamide/mesna and consolidation with ESHAP for refractory and relapsed non-Hodgkin's lymphomaJ E Romaguera, F B Hagemeister, P McLaughlin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1996
No effect of 96-hour paclitaxel infusion in patients with relapsed non-Hodgkin's lymphoma refractory to a 3-hour infusion scheduleA Younes, J P Ayoub, F B Hagemeister, et al.
Cancer|July 21, 1998
Colorectal carcinoma survival among hereditary nonpolyposis colorectal carcinoma family membersP Watson, K M Lin, M A Rodriguez-Bigas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 11, 1992
Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphomaJ R Redman, F Cabanillas, W S Velasquez, et al.
International Journal of Radiation Oncology, Biology, Physics|November 10, 2000
Impact of involved field radiotherapy after CHOP-based chemotherapy on stage III-IV, intermediate grade and large-cell immunoblastic lymphomasP J Schlembach, R B Wilder, S L Tucker, et al.
Clinical Lymphoma|November 15, 2001
Non-Hodgkin's lymphoma affecting the testis: is it curable with doxorubicin-based therapy?C Visco, L J Medeiros, O M Mesina, et al.
Pageof 34